Search our team at AdventHealth Research Institute
-
NCT05761171
AALL2121: A Phase 2 Study of SNDX-5613 in Combination with Chemotherapy for Patients with Relapsed or Refractory KMT2A-Rearranged Infant Leukemia
This study is currently enrolling.Associated Conditions: LeukemiaResearch Area: Cancer ResearchResearch Location: Orlando, FloridaThe overall goal of this study is to determine the safety and best dose of the drug SNDX-5613 for young children when given in combination with chemotherapy, and to see if this treatment will improve...
-
NCT05602194
A Randomized Trial of Levocarnitine Prophylaxis to Prevent Asparaginase-Associated Hepatotoxicity in Adolescents and Young Adults Receiving Acute Lymphoblastic Leukemia Therapy
This study is not currently enrolling.Associated Conditions: LeukemiaResearch Area: Pediatrics ResearchResearch Location: Orlando, FloridaThe overall goal of this study is to determine whether adding levocarnitine to standard of care ALL treatment will reduce the chances of developing severe liver damage from asparaginase chemotherapy.
-
NCT05918913
SNDX-5613-0707: Expanded Access Program for SNDX-5613 in Patients with Relapsed/Refractory Acute Leukemias with Genetic Alterations Associated with HOXA Overexpression
This study is currently enrolling.Associated Conditions: LeukemiaResearch Area: Cancer ResearchResearch Location: Orlando, FloridaThe therapy that will be receive involves being given the drug SNDX-5613 to treat Relapsed/Refractory acute leukemias, including those harboring an KMT2Ar Gene Rearrangement, Nucleophosmin 1 (NPM1m)...
-
NCT02981628
A Phase 2 Study of INotuzumab Ozogamicin (NSC# 772518, IND #133494) in Children and Young Adults with Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)
This study is currently enrolling.Associated Conditions: LeukemiaResearch Area: Cancer ResearchResearch Location: Orlando, FloridaThe overall goal of this study is to find out what effect, good and/or bad, the drug inotuzumab ozogamicin has on children and young adults with relapsed or refractory B-ALL.
-
NCT02723994
A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib with Chemotherapy in Children with De Novo High-Risk CRLF2-Rearranged and/or JAK Pathway-Mutant Acute Lymphoblastic Leukemia
This study is not currently enrolling.Associated Conditions: LeukemiaResearch Area: Pediatrics ResearchThe overall goal of this study are to: Part 1 - Find the best dose of ruxolitinib to use with standard chemotherapy in children, adolescents, and young adults with HR B-ALL; Part 2 - Find out if the...
-
NCT02521493
CIRB/COG AAML1531 Risk-stratified Therapy for Acute Myeloid Leukemia in Down Syndrome
This study is currently enrolling.Associated Conditions: Pediatric CancerResearch Area: Cancer ResearchResearch Location: Orlando, FloridaThe overall goals of this study are to: To find out if subjects with standard risk DS AML can be treated with less treatment and still have successful outcomes. To find out if subjects with high risk...
-
NCT0645646
A Phase II multicenter open-label trial of tagraxofusp (Tag) in combination with venetoclax and azacitidine (Ven/Aza) in adults with previously untreated CD123+ acute myeloid leukemia (AML) who are ineligible for intensive chemotherapy.
This study is not currently enrolling.Associated Conditions: LeukemiaResearch Area: Cancer ResearchResearch Location: Orlando, Florida -
NCT06456463
A Phase II multicenter open-label trial of tagraxofusp (Tag) in combination with venetoclax and azacitidine (Ven/Aza) in adults with previously untreated CD123+ acute myeloid leukemia (AML) who are ineligible for intensive chemotherapy.
This study is not currently enrolling.Associated Conditions: LeukemiaResearch Area: Cancer Research -
NCT03959085
A Phase 3 Randomized Trial of INotuzumab Ozogamicin (IND#: 133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy
This study is currently enrolling.Associated Conditions: LeukemiaResearch Area: Cancer ResearchDisseminated B-Cell Lymphoblastic Lymphoma (B-LLy): The overall goal of this study is to determine the outcomes of subjects with disseminated B-LLy receiving High Risk B-cell Acute Lymphoblastic...
-
NCT04836390
A Phase II Pilot Study of Donor-Derived Ex-VivoExpanded Natural Killer Cell Infusions in Childrenand Young Adults with High-Risk Acute Myeloid Leukemia Receiving Myeloablative HLA Haploidentical Hematopoietic Cell Transplant: A Multicenter Pediatric Transplantation and Cellular Therapy Consortium (PTCTC) Study (EXCEL Trial) PTCTC CT2001.
This study is currently enrolling.Associated Conditions: LeukemiaResearch Area: Cancer ResearchResearch Location: Orlando, FloridaParticipants will be invited to join this study if they have a blood disease called acute myeloid leukemia (AML) and it has been decided that they need a transplant as part of their treatment plan....
-
NCT06226571
A Phase 1, Open-label, Dose-escalation, and Dose-expansion Study to Evaluate Safety, Tolerability, and Clinical Activity of SNDX-5613 in Combination with Intensive Chemotherapy in Participants with Newly Diagnosed Acute Myeloid Leukemias Harboring Alterations in Lysine-specific Methyltransferase 2A (KMT2A/MLL), Nucleophosmin 1 (NPM1), and Nucleoporin 98 (NUP98) Genes
This study is currently enrolling.Research Area: Cancer ResearchResearch Location: Orlando, Florida -
NCT05457556
A Multi-Center, Phase 3, Randomized Trial of Matched Unrelated Donor (MUD) versus HLA-Haploidentical Related (Haplo) Myeloablative Hematopoietic Cell Transplantation for Children, Adolescents, and Young Adults (AYA) with Acute Leukemia or Myelodysplastic Syndrome (MDS)
This study is currently enrolling.Associated Conditions: Cancer, Multiple Tumor TypesResearch Area: Pediatrics ResearchResearch Location: Orlando, FloridaYou are being asked to take part in this research study because you have been diagnosed with acute leukemia or myelodysplastic syndrome (MDS).